טוען...

Novel Complement Inhibitor Limits Severity of Experimentally Myasthenia Gravis

OBJECTIVE: Complement mediated injury of the neuromuscular junction is considered a primary disease mechanism in human myasthenia gravis and animal models of experimentally acquired myasthenia gravis (EAMG). We utilized active and passive models of EAMG to investigate the efficacy of a novel C5 comp...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Soltys, Jindrich, Kusner, Linda L., Young, Andrew, Richmonds, Chelliah, Hatala, Denise, Gong, Bendi, Shanmugavel, Vaithesh, Kaminski, Henry J.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2009
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3045826/
https://ncbi.nlm.nih.gov/pubmed/19194881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ana.21536
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!